Jupiter Asset Administration Ltd. lowered its place in Pfizer Inc. (NYSE:PFE – Free Report) by 5.7% in the course of the 2nd quarter, in response to its most up-to-date submitting with the Securities and Alternate Fee (SEC). The institutional investor owned 109,435 shares of the biopharmaceutical firm’s inventory after promoting 6,654 shares in the course of the interval. Jupiter Asset Administration Ltd.’s holdings in Pfizer had been price $3,062,000 as of its most up-to-date SEC submitting.
Different institutional traders have additionally modified their holdings of the corporate. FAS Wealth Companions Inc. elevated its place in shares of Pfizer by 1.3% within the second quarter. FAS Wealth Companions Inc. now owns 26,306 shares of the biopharmaceutical firm’s inventory price $736,000 after buying a further 342 shares within the final quarter. Sachetta LLC raised its place in Pfizer by 7.3% within the second quarter. Sachetta LLC now owns 5,010 shares of the biopharmaceutical firm’s inventory valued at $140,000 after buying a further 342 shares in the course of the interval. Ironvine Capital Companions LLC lifted its stake in shares of Pfizer by 2.1% in the course of the first quarter. Ironvine Capital Companions LLC now owns 16,953 shares of the biopharmaceutical firm’s inventory price $470,000 after buying a further 353 shares within the final quarter. Safe Asset Administration LLC boosted its place in shares of Pfizer by 0.6% within the second quarter. Safe Asset Administration LLC now owns 58,328 shares of the biopharmaceutical firm’s inventory price $1,632,000 after shopping for a further 353 shares in the course of the interval. Lastly, Patrick M Sweeney & Associates Inc. grew its stake in shares of Pfizer by 0.8% within the second quarter. Patrick M Sweeney & Associates Inc. now owns 42,162 shares of the biopharmaceutical firm’s inventory valued at $1,180,000 after shopping for a further 355 shares within the final quarter. Hedge funds and different institutional traders personal 68.36% of the corporate’s inventory.
Pfizer Inventory Up 0.4 %
Shares of NYSE:PFE opened at $29.27 on Friday. The corporate’s fifty day transferring common is $29.21 and its two-hundred day transferring common is $28.11. The corporate has a debt-to-equity ratio of 0.65, a fast ratio of 0.60 and a present ratio of 0.86. Pfizer Inc. has a 1-year low of $25.20 and a 1-year excessive of $34.42. The inventory has a market capitalization of $165.86 billion, a price-to-earnings ratio of -487.75, a price-to-earnings-growth ratio of 1.04 and a beta of 0.68.
Pfizer (NYSE:PFE – Get Free Report) final launched its quarterly earnings knowledge on Tuesday, July thirtieth. The biopharmaceutical firm reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a adverse web margin of 4.66% and a optimistic return on fairness of 8.42%. The agency had income of $13.28 billion for the quarter, in comparison with analyst estimates of $12.96 billion. Throughout the identical quarter within the prior yr, the enterprise earned $0.67 earnings per share. Pfizer’s quarterly income was up 2.1% on a year-over-year foundation. Equities analysts anticipate that Pfizer Inc. will publish 2.66 EPS for the present yr.
Pfizer Dividend Announcement
The enterprise additionally just lately disclosed a quarterly dividend, which was paid on Tuesday, September third. Buyers of report on Friday, July twenty sixth got a dividend of $0.42 per share. The ex-dividend date of this dividend was Friday, July twenty sixth. This represents a $1.68 dividend on an annualized foundation and a yield of 5.74%. Pfizer’s dividend payout ratio is presently -2,799.53%.
Analysts Set New Worth Targets
A number of equities analysts just lately commented on PFE shares. Daiwa Capital Markets raised Pfizer from a “impartial” ranking to an “outperform” ranking and boosted their value goal for the inventory from $28.00 to $34.00 in a analysis report on Wednesday, August seventh. Daiwa America upgraded shares of Pfizer from a “reasonable purchase” ranking to a “strong-buy” ranking in a analysis word on Wednesday, August seventh. Cantor Fitzgerald reiterated an “chubby” ranking and issued a $45.00 value goal on shares of Pfizer in a report on Monday, September ninth. UBS Group raised their goal value on Pfizer from $30.00 to $31.00 and gave the corporate a “impartial” ranking in a analysis word on Wednesday, July thirty first. Lastly, Barclays boosted their value goal on Pfizer from $30.00 to $32.00 and gave the inventory an “equal weight” ranking in a analysis word on Wednesday, July thirty first. Eight analysts have rated the inventory with a maintain ranking, seven have given a purchase ranking and one has assigned a powerful purchase ranking to the inventory. In line with knowledge from MarketBeat.com, Pfizer has a consensus ranking of “Average Purchase” and a mean value goal of $34.54.
Learn Our Newest Report on PFE
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical merchandise in the USA, Europe, and internationally. The corporate presents medicines and vaccines in numerous therapeutic areas, together with cardiovascular metabolic, migraine, and ladies’s well being beneath the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin household manufacturers; infectious illnesses with unmet medical wants beneath the Prevnar household, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba manufacturers; and COVID-19 prevention and remedy, and potential future mRNA and antiviral merchandise beneath the Comirnaty and Paxlovid manufacturers.
See Additionally
Need to see what different hedge funds are holding PFE? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Obtain Information & Rankings for Pfizer Day by day – Enter your e mail handle beneath to obtain a concise each day abstract of the most recent information and analysts’ scores for Pfizer and associated corporations with MarketBeat.com’s FREE each day e mail e-newsletter.
